O Brien Greene & Co. Inc Invests $4.27 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

O Brien Greene & Co. Inc purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,837 shares of the company’s stock, valued at approximately $4,265,000. Medpace comprises 1.4% of O Brien Greene & Co. Inc’s portfolio, making the stock its 29th biggest position.

Other hedge funds have also modified their holdings of the company. Pallas Capital Advisors LLC increased its holdings in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after purchasing an additional 2,101 shares in the last quarter. Baillie Gifford & Co. lifted its position in shares of Medpace by 175.6% in the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after buying an additional 9,478 shares during the last quarter. Barclays PLC boosted its position in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. CWA Asset Management Group LLC bought a new stake in shares of Medpace during the third quarter worth approximately $1,306,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in shares of Medpace by 6.3% during the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after buying an additional 2,675 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of Medpace stock opened at $344.01 on Thursday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The firm has a market cap of $10.48 billion, a PE ratio of 27.24, a PEG ratio of 3.77 and a beta of 1.36. The company has a 50 day simple moving average of $343.28 and a two-hundred day simple moving average of $347.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of recent research reports. TD Cowen lowered their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Medpace has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.